Molecular Templates (MTEM) Stock Price, News & Analysis

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $0.0005 to $0.0005
• 50-Day Range: $0.00 to $0.40
• 52-Week Range: $0.00 to $4.12
• Volume: 258 shs
• Average Volume: 12,473 shs
• Market Capitalization: $3,290.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MTEM Stock Analysis - Frequently Asked Questions

How have MTEM shares performed this year?

Molecular Templates' stock was trading at $0.04 on January 1st, 2025. Since then, MTEM shares have decreased by 98.8% and is now trading at $0.0005.
View the best growth stocks for 2025 here.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) announced its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to analysts' expectations of $15.69 million. Molecular Templates had a negative net margin of 61.35% and a negative trailing twelve-month return on equity of 260.50%.

When did Molecular Templates' stock split?

Molecular Templates shares reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Molecular Templates' major shareholders?

Top institutional investors of Molecular Templates include Concourse Financial Group Securities Inc.. Insiders that own company stock include Shv Management Services, Llc, Sean Mclennan and Target N V Biotech.
View institutional ownership trends.

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 2/20/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MTEM
• CUSIP: 88580720
• CIK: 1183765
• Web: www.mtem.com
• Phone: (512) 869-1555
• Fax: 650-474-2529
• Employees: 260
• Year Founded: 2009

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,120,000.00
• Net Margins: -61.35%
• Pretax Margin: -61.39%
• Return on Equity: -260.50%
• Return on Assets: -46.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.56
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: $57.31 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 6,580,000
• Free Float: 5,669,000
• Market Cap: $3,290.00
• Optionable: No Data
• Beta: 1.19